title: The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.
abstract: . RA is associated with an increased risk of cardiovascular events (CVEs). The objective was to estimate independent effects of RA autoantibodies on the incident CVEs in patients with early RA.
  
  
  
  Patients were enrolled in the Canadian Early Inflammatory Arthritis Cohort, a prospective multicentre inception cohort. Incident CVEs, including acute coronary syndromes and cerebrovascular events, were self-reported by the patient and partially validated by medical chart review. Seropositive status was defined as either RF or ACPA positive. Multivariable Cox proportional hazards survival analysis was used to estimate the effects of seropositive status on incident CVEs, controlling for RA clinical variables and traditional cardiovascular risk factors.
  
  
  
  . A total of 2626 patients were included: the mean symptom duration at diagnosis was 6.3 months ( s . d . 4.6), the mean age was 53 years ( s . d . 15), 72% were female and 86% met classification criteria for RA. Forty-six incident CVEs occurred over 6483 person-years [incidence rate 7.1/1000 person-years (95% confidence interval 5.3, 9.4)]. The CVE rate did not differ in seropositive vs seronegative subjects and seropositivity was not associated with incident CVEs in multivariable Cox regression models. Baseline covariates independently associated with incident CVEs were older age, a history of hypertension and a longer duration of RA symptoms prior to diagnosis.
  
  
  
  The rate of CVEs early in the course of inflammatory arthritis was low; however, delays in the diagnosis of arthritis increased the rate of CVEs. Hypertension was the strongest independent risk factor for CVEs. Results support early aggressive management of RA disease activity and co-morbidities to prevent severe complications.
authors.affiliation: Department of Medicine, Division of Rheumatology, Western University, London, Ontario.
authors.forename: Lillian J
authors.initials: LJ
authors.lastname: Barra
authors.affiliation: Department of Medicine, Division of Rheumatology, Western University, London, Ontario.
authors.forename: Janet E
authors.initials: JE
authors.lastname: Pope
authors.affiliation: Department of Medicine, Division of Rheumatology, University of Manitoba, Winnipeg, Manitoba.
authors.forename: Carol
authors.initials: C
authors.lastname: Hitchon
authors.affiliation: Department of Medicine, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec.
authors.forename: Gilles
authors.initials: G
authors.lastname: Boire
authors.affiliation: Department of Epidemiology, University of Toronto Dalla Lana School of Public Health.
authors.forename: Orit
authors.initials: O
authors.lastname: Schieir
authors.affiliation: Department of Medicine, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto.
authors.forename: Daming
authors.initials: D
authors.lastname: Lin
authors.affiliation: Arthritis Program Southlake Regional Health Center, Newmarket, Ontario.
authors.forename: Carter J
authors.initials: CJ
authors.lastname: Thorne
authors.affiliation: Arthritis Program Southlake Regional Health Center, Newmarket, Ontario.
authors.forename: Diane
authors.initials: D
authors.lastname: Tin
authors.affiliation: Department of Medicine, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto.
authors.forename: Edward C
authors.initials: EC
authors.lastname: Keystone
authors.affiliation: Department of Medicine, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, Quebec.
authors.forename: Boulos
authors.initials: B
authors.lastname: Haraoui
authors.affiliation: Department of Medicine, Vancouver Coastal Health, Vancouver, British Columbia, Canada.
authors.forename: Shahin
authors.initials: S
authors.lastname: Jamal
authors.affiliation: Department of Medicine, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto.|Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA.
authors.forename: Vivian P
authors.initials: VP
authors.lastname: Bykerk
mesh_terms: D000704:Analysis of Variance; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D001323:Autoantibodies / Q000378:metabolism*; D002170:Canada / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000209:etiology; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology; D011446:Prospective Studies; D012217:Rheumatoid Factor / Q000378:metabolism; D012307:Risk Factors
chemical_list: D018501:Antirheumatic Agents; D001323:Autoantibodies; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D012217:Rheumatoid Factor
keywords: ACPA; RF; cardiovascular disease; complications; rheumatoid arthritis; seropositive